UroGen Pharma ( NASDAQ: URGN) closed Friday up ~43%, a week before the U.S. FDA is set to act on its NDA for UGN-102 (mitomycin), a treatment for a type of bladder cancer. It is not immediately clear ...

Despite robust fundamentals, Cintas trades at a premium valuation. Click here to find out why I am neutral on CTAS stock.